Get started
Author

Arliene Ravelo

Prevalence and Costs of Chronic Conditions in the VA Health Care System
2003 · Wei Yu, Arliene Ravelo, et al. · Medical Care Research and Review · 282
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
2015 · Martin J.B. Taphoorn, Roger Henriksson, et al. · Journal of Clinical Oncology · 136
PDF
The relationships among age, chronic conditions, and healthcare costs.
2004 · Wei Yu, Arliene Ravelo, et al. · PubMed · 58
Cost Analysis of Interventions for Antimuscarinic Refractory Patients With Overactive Bladder
2010 · Jonathan H. Watanabe, Jonathan D. Campbell, et al. · Urology · 47
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer
2019 · Carolina Reyes, Nicole M. Engel-Nitz, et al. · The Oncologist · 41
PDF
Overall survival in patients with glioblastoma before and after bevacizumab approval
2017 · Derek R. Johnson, Antonio M. P. Omuro, et al. · Current Medical Research and Opinion · 40
Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
2013 · Roger Henriksson, Andrew Bottomley, et al. · Journal of Clinical Oncology · 36
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
2009 · Jonathan D Campbell, Katharine S Gries, et al. · BMC Urology · 32
PDF
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare
2015 · Joshua A. Roth, Sean D. Sullivan, et al. · Journal of Oncology Practice · 30
Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network
2011 · Eric Nadler, Elaine Yu, et al. · The Oncologist · 30
PDF
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib
2017 · J. J. Carlson, W. Canestaro, et al. · Journal of Medical Economics · 26
PDF
Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings
2017 · Mark S. Walker, William Wong, et al. · Clinical Lung Cancer · 22
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
2021 · Anuja Chatterjee, Sheila Shapouri, et al. · Journal of Managed Care & Specialty Pharmacy · 19
PDF
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
2020 · Sang Kyu Cho, Beenish S. Manzoor, et al. · PharmacoEconomics · 19
PDF
Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma
2019 · Carolina Reyes, Nicole M. Engel-Nitz, et al. · The Oncologist · 19
PDF
Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes
2010 · William Hollingworth, Jonathan D. Campbell, et al. · Quality of Life Research · 19
Oncologists’ Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey
2018 · Bijal Shah-Manek, William Wong, et al. · Journal of Managed Care & Specialty Pharmacy · 17
PDF
Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study
2017 · Mark S. Walker, William Wong, et al. · Health and Quality of Life Outcomes · 16
PDF
First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices
2016 · Orsolya E. Lunacsek, Arliene Ravelo, et al. · Drugs - Real World Outcomes · 16
PDF
Fostering a High-Functioning Team in Cancer Care Using the 4R Oncology Model: Assessment in a Large Health System and a Blueprint for Other Institutions
2022 · Raymond Liu, Christine B. Weldon, et al. · JCO Oncology Practice · 13
PDF
Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
2019 · Annick Desjardins, James E. Herndon, et al. · Health Science Reports · 13
PDF
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States
2019 · Matthew S. Davids, Anuja Chatterjee, et al. · Blood · 11
Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer
2017 · Apar Kishor Ganti, Fred R. Hirsch, et al. · Clinical Lung Cancer · 11
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
2015 · Clara Chen, Arliene Ravelo, et al. · Journal of Neuro-Oncology · 11
PDF
Oncology Comparative Effectiveness Research: A Multistakeholder Perspective on Principles for Conduct and Reporting
2013 · Scott D. Ramsey, Sean D. Sullivan, et al. · The Oncologist · 11
PDF
Works count: 132
Citation count: 1,117
H-index: 17
I10-index: 27
Year
Topic
Type